Could somebody please do my maths:
if we assume Invokana market share is US$668B and PD becomes a complementary test.. the income from the partnership with Jansen could be quite something.
But I'm not smart enough to understand - If/How this be extrapolated..?
I'm not sure on the number of tests required each year by each patient and if this can be measured directly against the cost of Invokana to project a future value of the company based at this point solely on its DKD Promarker D stuff..
Ann: Proteomics International seeks FDA approval for PromarkerD, page-162
-
- There are more pages in this discussion • 161 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
90.0¢ |
Change
0.020(2.27%) |
Mkt cap ! $117.9M | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 92.5¢ | 87.0¢ | $198.7K | 220.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4904 | 90.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |